BioAspect is pleased to be the premier distributor of Absolute Antibody products in North America. Absolute Antibody manufactures all recombinant antibodies from publicly available sequences, licensed sequences, or sequences obtained from sequencing licensed hybridomas. The products are manufactured using Absolute Antibody's proprietary cloning system that allows production of monoclonal antibodies and fusion proteins in multiple formats. For a full list of primary monoclonal antibodies from Absolute Antibody click here.
BioAspect also brings to North America a selection of research grade biosimilars (monoclonal antibodies and Fc fusion proteins) manufactured using a proprietary Absolute Antibody's recombinant platform. The growing range of research grade biosimilars available from Absolute Antibody includes Trastuzumab, Muromonab, Campath, Rituximab, Infliximab, Daclizumab, Basiliximab, Cetuximab, Satumomab, Acritumomab, Abaciximab, and Eculizumab.
These products are for research purposes only and can be used as positive controls in discovery and development of novel biotherapeutics, and for the development of potency assays.
All research grade biosimilars are supplied in PBS buffer with preservative (0.02% Proclin 300), are of high purity (>98% as determined by SDS-PAGE), and endotoxin free (< 1.0 EU/mg as determined by the LAL method).